UA89615C2 - Фармацевтические композиции, которые содержат никотиновую кислоту и антагонист рецептора dp - Google Patents

Фармацевтические композиции, которые содержат никотиновую кислоту и антагонист рецептора dp

Info

Publication number
UA89615C2
UA89615C2 UAA200512018A UAA200512018A UA89615C2 UA 89615 C2 UA89615 C2 UA 89615C2 UA A200512018 A UAA200512018 A UA A200512018A UA A200512018 A UAA200512018 A UA A200512018A UA 89615 C2 UA89615 C2 UA 89615C2
Authority
UA
Ukraine
Prior art keywords
nicotinic acid
receptor antagonist
pharmaceutical compositions
administered
receptor
Prior art date
Application number
UAA200512018A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кан Чен
Джерард Уотерс
Кетлин М. Меттерс
Гери ОНейл
Original Assignee
Мерк Энд Ко., Инк.
Мерк Фросст Кенада Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA89615(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Энд Ко., Инк., Мерк Фросст Кенада Лтд. filed Critical Мерк Энд Ко., Инк.
Publication of UA89615C2 publication Critical patent/UA89615C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Изобретение относится к области медицины и касается фармацевтической композиции, которая содержит никотиновую кислоту и антагонист рецептора DP. Композиция дополнительно может содержать ингибитор редуктазы HMG Co-A.
UAA200512018A 2003-05-15 2004-05-13 Фармацевтические композиции, которые содержат никотиновую кислоту и антагонист рецептора dp UA89615C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47066503P 2003-05-15 2003-05-15

Publications (1)

Publication Number Publication Date
UA89615C2 true UA89615C2 (ru) 2010-02-25

Family

ID=33476734

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200512018A UA89615C2 (ru) 2003-05-15 2004-05-13 Фармацевтические композиции, которые содержат никотиновую кислоту и антагонист рецептора dp

Country Status (44)

Country Link
US (4) US20040229844A1 (ru)
EP (3) EP1624871B1 (ru)
JP (2) JP4637833B2 (ru)
KR (2) KR100960749B1 (ru)
CN (3) CN101559227B (ru)
AR (1) AR041089A1 (ru)
AU (2) AU2004240597B2 (ru)
BR (1) BRPI0410273A (ru)
CA (1) CA2525772C (ru)
CL (1) CL2004001056A1 (ru)
CO (1) CO5630034A2 (ru)
CR (2) CR8047A (ru)
CY (2) CY1109476T1 (ru)
DE (1) DE602004022036D1 (ru)
DK (2) DK2116244T3 (ru)
DO (1) DOP2004000907A (ru)
EA (2) EA009744B1 (ru)
EC (1) ECSP056156A (ru)
ES (2) ES2392743T3 (ru)
GE (2) GEP20105025B (ru)
GT (1) GT200400098A (ru)
HN (1) HN2004000171A (ru)
HR (2) HRP20090424T1 (ru)
IL (1) IL171962A (ru)
IS (1) IS2708B (ru)
JO (1) JO2564B1 (ru)
MA (1) MA27835A1 (ru)
ME (1) MEP60108A (ru)
MX (1) MXPA05012272A (ru)
MY (1) MY140639A (ru)
NO (1) NO20055957L (ru)
NZ (2) NZ543399A (ru)
PA (1) PA8603201A1 (ru)
PE (1) PE20050552A1 (ru)
PL (2) PL2116244T3 (ru)
PT (2) PT2116244E (ru)
RS (3) RS20120499A1 (ru)
SG (1) SG153667A1 (ru)
SI (2) SI2116244T1 (ru)
TN (1) TNSN05290A1 (ru)
TW (2) TWI334354B (ru)
UA (1) UA89615C2 (ru)
WO (1) WO2004103370A1 (ru)
ZA (1) ZA200508288B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE340796T1 (de) * 2001-05-23 2006-10-15 Merck Frosst Canada Inc Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten
US7094572B2 (en) * 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
SI2801354T1 (sl) 2004-10-08 2017-07-31 Forward Pharma A/S Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006078776A2 (en) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
AU2006214018A1 (en) * 2005-02-17 2006-08-24 Merck Sharp & Dohme Corp. Method of treating atherosclerosis, dyslipidemias and related conditions
AU2006214286A1 (en) * 2005-02-18 2006-08-24 Arena Pharmaceuticals, Inc. Methods and compositions for the treatment of lipid-associated disorders
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7723342B2 (en) * 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
JP2009507791A (ja) * 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
US20070049603A1 (en) * 2005-09-01 2007-03-01 Greg Miknis Raf inhibitor compounds and methods of use thereof
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
BRPI0620386A2 (pt) * 2005-12-21 2011-12-20 Schering Corp composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição
CA2634940A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
KR20080091814A (ko) * 2006-01-20 2008-10-14 쉐링 코포레이션 지질혈증장애의 치료를 위한 니코틴산 수용체 효능제로서의헤테로사이클
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
US20080070890A1 (en) * 2006-09-15 2008-03-20 Burnett Duane A Spirocyclic Azetidinone Compounds and Methods of Use Thereof
CA2663503A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
MX2009002921A (es) * 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
EP2114154B1 (en) * 2007-02-08 2013-08-28 Merck Sharp & Dohme Corp. Method of treating atherosclerosis, dyslipidemias and related conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
CN101559058B (zh) * 2008-04-16 2011-07-20 北京本草天源药物研究院 一种治疗血脂异常的药物组合物
AU2009249600A1 (en) * 2008-05-20 2009-11-26 Cerenis Therapeutics Holding S.A. Niacin and NSAID for combination therapy
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
US20110165239A1 (en) * 2008-09-24 2011-07-07 Laman Alani Pharmaceutical compositions of atorvastatin
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
KR101699912B1 (ko) 2009-01-09 2017-01-25 포워드 파마 에이/에스 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
CA2793324A1 (en) 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. A substituted pyrimidine as a prostaglandin d2 receptor antagonist
AR080590A1 (es) 2010-03-16 2012-04-18 Aventis Pharma Inc Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2
WO2016128565A1 (en) 2015-02-13 2016-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
JPS6352514B2 (ru) 1977-09-30 1988-10-19 Rca Corp
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
CA2218696A1 (en) * 1995-04-19 1996-10-24 L. Jackson Ii Roberts Compositions, kits and methods for administration of antilipemic and an ti-platelet aggregation drugs
DE69621952T2 (de) 1995-10-31 2003-01-16 Schering Corp., Kenilworth Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
AU7472896A (en) 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
DE69625046T2 (de) 1995-12-22 2003-04-10 Kowa Co., Ltd. Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
DE69841395D1 (de) * 1997-07-31 2010-01-28 Abbott Respiratory Llc Zusammensetzung enthaltend einen HMG-CoA-Reduktasehemmer und eine Nikotinsäureverbindung zur Behandlung von Hyperlipidämie
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
BR9812770A (pt) * 1997-10-27 2000-12-12 Reddy Research Foundation Compostos bicìclicos, processo para seu preparo e composições farmacêuticas contendo os mesmos
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
CA2353981C (en) 1998-12-07 2005-04-26 Schering Corporation Process for the synthesis of azetidinones
CN1342091A (zh) 1998-12-23 2002-03-27 G.D.瑟尔有限公司 心血管指征的联合用药
EP2281899A3 (en) 1999-04-05 2012-01-04 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-3(S)-hydroxy-3-(4-fluorophenyl)propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone
AR023463A1 (es) 1999-04-16 2002-09-04 Schering Corp Uso de compuestos de azetidinona
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
US6743793B2 (en) 2000-03-09 2004-06-01 Ono Pharmaceutical Co., Ltd. Indole derivatives, process for preparation of the same and use thereof
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2002008186A (ja) * 2000-06-23 2002-01-11 Mitsubishi Heavy Ind Ltd 車種識別装置
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) * 2000-09-13 2007-03-07 三洋電機株式会社 映像信号処理回路
US20040254224A1 (en) 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
ATE340796T1 (de) * 2001-05-23 2006-10-15 Merck Frosst Canada Inc Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten
KR20040044856A (ko) 2001-09-07 2004-05-31 오노 야꾸힝 고교 가부시키가이샤 인돌 유도체 화합물
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
MXPA04009095A (es) 2002-03-19 2004-12-06 Ono Pharmaceutical Co Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo.
SG154333A1 (en) * 2002-06-03 2009-08-28 Novartis Ag The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) * 2005-07-01 2008-08-06 タキゲン製造株式会社 ステー

Also Published As

Publication number Publication date
US20090233977A1 (en) 2009-09-17
MA27835A1 (fr) 2006-04-03
PL1624871T3 (pl) 2009-12-31
DK2116244T3 (da) 2012-11-26
RS52731B (sr) 2013-08-30
SI1624871T1 (sl) 2009-12-31
MY140639A (en) 2010-01-15
AR041089A1 (es) 2005-05-04
ES2328148T3 (es) 2009-11-10
IL171962A0 (en) 2006-04-10
HK1092722A1 (zh) 2007-02-16
EP1624871A1 (en) 2006-02-15
KR20080003470A (ko) 2008-01-07
TWI341199B (en) 2011-05-01
KR20060012617A (ko) 2006-02-08
HRP20090424T1 (en) 2009-09-30
US20110118292A1 (en) 2011-05-19
IS8071A (is) 2005-10-13
SG153667A1 (en) 2009-07-29
US20040229844A1 (en) 2004-11-18
EP2286816A1 (en) 2011-02-23
NZ572515A (en) 2010-07-30
CN102526735A (zh) 2012-07-04
JP4637833B2 (ja) 2011-02-23
MXPA05012272A (es) 2006-05-19
TW200803844A (en) 2008-01-16
JO2564B1 (en) 2010-11-03
PT1624871E (pt) 2009-09-07
EP1624871B1 (en) 2009-07-15
EP2116244B1 (en) 2012-08-08
BRPI0410273A (pt) 2006-05-16
PT2116244E (pt) 2012-11-02
NO20055957L (no) 2006-02-14
GEP20084569B (en) 2008-12-25
TW200503757A (en) 2005-02-01
CN101559227A (zh) 2009-10-21
AU2011200986A1 (en) 2011-03-31
CN1787819A (zh) 2006-06-14
CO5630034A2 (es) 2006-04-28
HRP20120818T1 (hr) 2012-11-30
AU2004240597A1 (en) 2004-12-02
PL2116244T3 (pl) 2013-01-31
KR100960749B1 (ko) 2010-06-01
DK1624871T3 (da) 2009-11-16
WO2004103370A1 (en) 2004-12-02
DOP2004000907A (es) 2004-11-30
KR100806008B1 (ko) 2008-02-26
TWI334354B (en) 2010-12-11
CN100441184C (zh) 2008-12-10
HN2004000171A (es) 2011-07-11
PA8603201A1 (es) 2005-02-04
CY1113342T1 (el) 2016-06-22
IS2708B (is) 2011-01-15
EA009744B1 (ru) 2008-04-28
CR8047A (es) 2006-07-14
CY1109476T1 (el) 2014-08-13
JP2006526030A (ja) 2006-11-16
DE602004022036D1 (de) 2009-08-27
CN101559227B (zh) 2012-03-21
GEP20105025B (en) 2010-06-25
EA200501817A1 (ru) 2006-06-30
TNSN05290A1 (en) 2007-07-10
NZ543399A (en) 2009-02-28
EA200702674A1 (ru) 2008-04-28
ZA200508288B (en) 2008-08-27
US20100076002A1 (en) 2010-03-25
CA2525772C (en) 2011-03-15
RS20050777A (sr) 2008-04-04
RS20120499A1 (sr) 2013-08-30
ECSP056156A (es) 2006-04-19
CA2525772A1 (en) 2004-12-02
RS20120498A1 (sr) 2013-08-30
JP2010077151A (ja) 2010-04-08
EP2116244A1 (en) 2009-11-11
GT200400098A (es) 2005-03-03
SI2116244T1 (sl) 2012-12-31
IL171962A (en) 2012-06-28
ES2392743T3 (es) 2012-12-13
CL2004001056A1 (es) 2005-03-28
EA011895B1 (ru) 2009-06-30
AU2004240597B2 (en) 2011-01-06
CR9808A (es) 2008-07-29
MEP60108A (en) 2011-05-10
PE20050552A1 (es) 2005-08-06
AU2011200986B2 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
JO2564B1 (en) A method for treating atherosclerosis, lipodystrophy and related conditions and pharmaceutical compositions
WO2006089309A3 (en) Method of treating atherosclerosis, dyslipidemias and related conditions
WO2007048026A3 (en) Cgrp peptide antagonists and conjugates
WO2005107726A3 (en) Method for the treatment of back pain
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
WO2004045579A3 (en) Pharmaceutical compositions and dosage forms of thalidomide
WO2005102338A8 (en) Method of treating neuropathic pain using a crth2 receptor antagonist
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2004071423A3 (en) Methods of administering opioid antagonists and compositions thereof
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2008097535A3 (en) Method of treating atherosclerosis, dyslipidemias and related conditions
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
EP1387685A4 (en) ANALGETIC COMPOSITION AND METHOD
GB0201367D0 (en) Composition
WO2006047392A3 (en) Nicotinic-opioid synergy for analgesia
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
MX2009004081A (es) Metodo para restaurar el efecto de incretina.
WO2006026273A3 (en) Method of treating atherosclerosis, dyslipidemias and related conditions
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
GB0211230D0 (en) Treatment of heart failure